Malignant Glioma
Malignant Glioma - Related Videos
09:43
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
0 Views •
Cited by 10 •
2014
Malignant gliomas constitute a heterogeneous group of highly infiltrative glial neoplasms with distinct clinical and molecular features. Primary orthotopic xenografts recapitulate the histopathological and molecular features of malignant glioma subtypes in preclinical animal models.
02:41
Assessing Glutamatergic Neurons and Glioma Cells Interactions in a Co-Culture
0 Views •
2025
This video demonstrates the assessment of neuronal electrical activity in a co-culture of hiPSC-derived cortical glutamatergic neurons and glioma cells using a microfluidic device with multielectrode arrays.
04:27
Co-culturing Glutamatergic Neurons and Pediatric High-Grade Glioma Cells
0 Views •
2025
This video showcases a technique for co-culturing glutamatergic neurons and pediatric high-grade glioma (pHGG) cells within a microfluidic device. Human induced pluripotent stem cells are introduced into the microfluidic system and incubated to promote their differentiation into mature cortical glutamatergic neurons. Following this, the pHGG cells are introduced onto the mature neurons, establishing a co-culture and enabling interactions between neurons and pHGG cells.
08:32
Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
0 Views •
Cited by 9 •
2019
Transgenic lck:eGFP zebrafish express GFP highly in T lymphocytes, and have been used to study T cell development and acute lymphoblastic leukemia. This line can be used to study B cells, which express lck at lower levels. This protocol describes purification of malignant and non-malignant B cells from lck:eGFP zebrafish.
03:55
Isolation of Nuclei from Fresh Frozen Glioma Tissues: A Method to Obtain Intact Nuclei from Glioma Tumor Samples
0 Views •
2023
This video describes the protocol to isolate single-nuclei from fresh frozen glioma tissue. The isolated single-nuclei can be used as specimens for sequencing techniques such as single-nuclei RNA (snRNA) sequencing and single-nuclei Assay for Transposase-Accessible Chromatin (snATAC) sequencing to obtain deeper insights into inter- and intra-tumor heterogeneity observed in glioma of the central nervous tissues.
FAQs
Infiltrative growth allows tumor cells to extend into surrounding brain tissue rather than remaining within a sharply defined mass. This makes it difficult to distinguish every abnormal cell from nearby tissue that may be important for brain function. Consequently, surgery aims for maximal safe removal, balancing reduction of tumor burden with preservation of the surrounding brain.
Molecular alterations can disrupt normal mechanisms that regulate cell growth, contributing to rapid proliferation and aggressive tumor behavior. Because tumors with similar appearances may have different molecular features, tissue analysis and molecular profiling add information beyond routine microscopic examination. These results help classify the tumor and may guide treatment planning or research into targeted therapies.
The blood-brain barrier can restrict the movement of drugs from the circulation into brain tissue, limiting how effectively some treatments reach tumor cells. This delivery challenge is an important consideration when chemotherapy and newer therapeutic strategies are evaluated. It also helps explain why treatment development includes approaches designed to improve effectiveness within the brain.
Evaluation combines a neurological assessment, magnetic resonance imaging, tissue pathology, and molecular profiling. The neurological assessment provides clinical information, while imaging shows the lesion and its location. Pathology examines the tumor tissue, and molecular testing identifies relevant alterations. Together, these findings support classification and help clinicians select an appropriate management strategy.
No single treatment component addresses every challenge posed by these tumors. Maximal safe surgery can reduce the visible tumor burden, while radiation and chemotherapy provide additional treatment after or around the surgical intervention. Combining these approaches reflects the tumor’s infiltrative growth and rapid proliferation, with care shaped by diagnostic and molecular findings.
Research is examining tumor genetics, targeted therapies, and immunotherapy to improve outcomes beyond established treatment combinations. Genetic studies may clarify how growth-control pathways become disrupted, while targeted approaches seek to address relevant tumor features. Immunotherapy represents another strategy under investigation. These efforts aim to improve survival while also preserving or enhancing quality of life.